The latest from CDMOs, CMOs, and suppliers featuring Vetter and Adragos Pharma.  

Formulation Development/Drug Product Manufacturing 
* Vetter’s European Clinical Injectable Site Receives Permanent Manufacturer’s Authorization 
* Adragos Pharma Acquires Sterile Mfg Facility from Fresenius Kabi 

---

Formulation Development/Drug Product Manufacturing 

Vetter’s European Clinical Injectable Site Receives Permanent Manufacturer’s Authorization 
Vetter, a Ravensburg, Germany-headquartered CDMO of aseptic filling and packaging, has received the permanent manufacturer’s authorization for its clinical development site in Rankweil, Austria.  

Before commissioning the site, the authority had already carried out an initial inspection at the end of 2021, which resulted in a temporary manufacturer’s authorization for two years, as is customary in Austria. 

Source: Vetter 

---

Adragos Pharma To Acquire Sterile Mfg Facility from Fresenius Kabi 
Adragos Pharma, a Munich, Germany-based CDMO, has agreed to acquire a sterile manufacturing facility in Halden, Norway from Fresenius Kabi, a Bad Homburg, Germany-based bio/pharmaceutical company.  

As part of the transaction, Fresenius Kabi will strike a long-term supply agreement for products manufactured at the Halden site.  

The Halden site’s capabilities include the production of IV bags, ampoules, blow-fill-seal technology, and other pharmaceutical dosage forms.  

The transaction is subject to customary conditions precedents. 

Source: Adragos Pharma